The federal court overseeing pretrial proceedings for hundreds of peripheral neuropathy lawsuits filed against the manufacturers of Levaquin and other fluoroquinolone antibiotics convened it most recent Status Conference in December. Minutes posted on the Court’s website indicate that discussions focused on discovery, bellwether trials and a number of other matters.

There are now more than 700 fluoroquinolone lawsuits pending in the U.S. District Court, District of Minnesota, which serves as the venue for the federal peripheral neuropathy litigation. At least 548 of those lawsuits involve Levaquin, while the remaining cases involve Cipro and Avelox. The Minutes also indicated that 30 cases are now pending in Pennsylvania state court, while one is pending in California state court.

During the proceeding’s December 1st  Status Conference, the parties reported that they are engaged in further discussions regarding the proposed bellwether trial protocols, and asked the Court to delay entering an order, so that they could seek an agreement. It was also reported that the parties continue to meet and confer on discovery. If they cannot resolve disputes, they will submit a motion to the Court. It was also noted that Plaintiffs agreed to dismiss McKesson from all cases within the litigation.

Finally, the Minutes indicated that the Court will convene its next Status Conference on February 21, 2017 at 2:00 p.m. CST.

Peripheral Neuropathy Allegations

Fuoroquinolone antibiotics, including Levaquin, Cipro and Avelox, are indicated to treat pneumonia and other serious bacterial infections. In August 2013, the U.S. Food & Drug Administration (FDA) required fluoroquinolone manufacturers to strengthen peripheral neuropathy warnings included on the labels. Plaintiffs pursuing Levaquin lawsuits and other fluoroquinolone cases claim that until 2013, the drugs’ labeling wrongly characterized peripheral neuropathy as a rare occurrence, and implied that the injury could be avoided by discontinuing treatment. Their complaints also note that the language regarding peripheral neuropathy was “buried at the end of a long list of adverse reactions” and not highlighted in a way that would benefit doctors or patients.

Bernstein Liebhard LLP represents plaintiffs who allegedly suffered serious complications, including peripheral neuropathy, aortic dissection, and aortic aneurysm, due to their use of Levaquin and other fluoroquinolone antibiotics. To discuss filing a lawsuit of our own, please contact our office by calling 877-779-1414 today.

Published January 18, 2017 by